Our attorneys have filed a mass tort lawsuit on behalf of patients who took the blood thinner Xarelto (rivaroxaban) and suffered critical bleeding events. Pharmaceutical firms, such as the makers of Xarelto, possess a duty to make sure that their drugs are reasonably secure for use – and failure to do so may possibly be grounds for compensation. Our lawyers are working difficult to get these hurt by the drug the compensation they are entitled to.
Even though bleeding can be a widespread complication connected with anticoagulants, it has been alleged that Xarelto is more hazardous than traditional blood thinners because no antidote exists to reverse its blood-thinning effects. This indicates that, within the occasion of an emergency, patients may be at danger for irreversible bleeding difficulties, like life-threatening internal and gastrointestinal hemorrhaging.
Should you or even a loved one particular suffered a significant bleeding event following taking Xarelto, you might have legal recourse. For far more details, speak to us today to possess your case reviewed, free of charge of charge.
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for previous and future medical bills, lost wages, pain and suffering and, in circumstances of death, funeral costs. Furthermore, they are seeking punitive damages, which are generally awarded to punish the defendant and deter other businesses from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike classic anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Since of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding within the event of an emergency. Plaintiffs within the lawsuits allege severe and fatal injuries, which includes cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a secure anticoagulant option.
Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user inside the event of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to significant bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing unsafe clotting.
Visit this page for more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys in the Complex read Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.